Production method of haemophilus parasuis/mycoplasma hyopneumoniae bivalent inactivated vaccine

Abstract

The invention belongs to the technical field of vaccine production, and particularly discloses a production method of a haemophilus parasuis / mycoplasma hyopneumoniae bivalent inactivated vaccine. Themethod includes: performing fermenting culture of mycoplasma hyopneumoniae in a bioreactor; performing fermenting culture of serum IV type haemophilus parasuis and serum V type haemophilus parasuis ina fermentation tank; inactivating, concentrating and purifying the microbial liquids after the fermenting cultivation, mixing the microbial liquids according to certain ratio, and adding an immuno-enhancer and a vaccine adjuvant to obtain the haemophilus parasuis / mycoplasma hyopneumoniae bivalent inactivated vaccine. The vaccine composition has excellent specificity and good immunity, can achievethe object of prevention from the two diseases by one injection, is more economical and practicability, can avoid repeated inoculation and reduces vaccine cost and manpower cost. The bivalent inactivated vaccine is very suitable for prevention and treatment on breeding farms with mixed infection of the diseases.

Description

technical field [0001] The invention belongs to the technical field of vaccine production, and in particular relates to the production of a dual inactivated vaccine of Haemophilus parasuis and Mycoplasma hyopneumoniae. Background technique [0002] Haemophilus parasuis has been one of the most important bacterial diseases among swine diseases in recent years, seriously affecting the healthy development of pig industry in my country. Haemophilus parasuis (HPS) can cause polyserositis, arthritis, and meningitis in pigs, which can affect suckling piglets from 2 weeks old to 4-month-old fattening pigs, mainly after weaning and nursery. Stage morbidity, more common in pigs of 5 to 8 weeks of age, the incidence rate is generally 10% to 15%, and the case fatality rate is as high as 50% when severe. The present invention analyzes all bacteria isolated from 2013 to 2017, and the results show that the isolation rate of Haemophilus parasuis reaches about 30.8%, among which the isolate...

AI Technical Summary

Problems solved by technology

[0005] However, due to combination vaccines (vaccine compositions), such as double vaccines or triple vaccines, multiple antigens interfere or affect each other, resulting in no dual vaccines for parasuis and mycoplasma pneumoniae currently on the market. The product

[0006] Not only that, the vaccines related to mycoplasma pneumonia recorded in the existing literature are mostly cultivated in fermenters. Due to the long cultivation time, the cost of manpower and production is increased, and the risk of contamination is increased.

Images